AIM: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian @entity1 with @entity2175 ( @entity2175 ) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A1chieve study. MATERIALS AND METHODS: Indian @entity1 with @entity2175 switching from pre-study IGlaror NPH insulin to IDet were included. Safety and effectiveness outcomes were evaluated by the physicians in local clinical settings. RESULTS: A total of 102 @entity1 switched from IGlar to IDet (GLA group) and 39 @entity1 switched from NPH insulin to IDet (NEU group). At baseline, the mean glycated hemoglobin A1c (HbA1c) levels were 9.9    1.8% in the GLA group and 9.1    1.2% in the NEU group. No serious adverse drug reactions, serious adverse events, or major hypoglycemic events were reported in either group throughout the study. At baseline and Week 24, 11.8% and 7.5% of @entity1 , respectively, reported overall hypoglycemic events in the GLA group. No hypoglycemic events were reported at Week 24 in the NEU group. At Week 24, the mean HbA1c levels were 7.6    0.9% in the GLA group and 7.3    0.7% in the NEU group. The mean fasting plasma @entity413 , postprandial plasma @entity413 and quality of life also appeared to improve over 24 weeks. CONCLUSION: Switching to IDet therapy from IGlar and NPH insulin was well-tolerated and appeared to be associated with improved glycogenic control in Indian @entity1 .

Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in XXXX : Observations from the Indian cohort in the A1chieve study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes', 'T2D']
@entity2175 :: (MESH:D003924,Disease) :: ['type 2 diabetes']
